Genelux Corporation (GNLX) 10-Year Financial Performance & Capital Metrics

GNLX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutGenelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Show more

Revenue $8K -95.3%
EBITDA -$31M -33.0%
Net Income -$30M -5.6%
EPS (Diluted) -0.95 +18.1%
Gross Margin -11187.5% -2142.8%
EBITDA Margin -384912.5% -2726.9%
Operating Margin -396200% -2687.3%
Net Margin -373362.5% -2143.1%
ROE -130.58% +10.1%
ROIC -147.88% +88.8%
Debt/Equity 0.07 -45.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 10 (bottom 10%)
✗Shares diluted 28.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-15.24%

EPS CAGR

10Y-

5Y-

3Y-

TTM6.32%

ROCE

10Y Avg-121.11%

5Y Avg-121.11%

3Y Avg-121.11%

Latest-128.97%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	11.07M	170K	8K
Revenue Growth %	-	-	-	-	-0.98%	-0.95%
Cost of Goods Sold+	0	658K	895K	968K	1.02M	903K
COGS % of Revenue	-	-	-	0.09%	5.99%	112.88%
Gross Profit+	0	-658K	-895K	10.1M	-848K	-895K
Gross Margin %	-	-	-	0.91%	-4.99%	-111.88%
Gross Profit Growth %	-	-	-0.36%	12.28%	-1.08%	-0.06%
Operating Expenses+	10.87M	11.76M	13.72M	13.11M	23.32M	30.8M
OpEx % of Revenue	-	-	-	1.18%	137.16%	3850.13%
Selling, General & Admin	3.34M	6.2M	8.29M	5M	11.57M	12.71M
SG&A % of Revenue	-	-	-	0.45%	68.05%	1588.25%
Research & Development	7.53M	6.23M	6.32M	9.08M	12.77M	19M
R&D % of Revenue	-	-	-	0.82%	75.1%	2374.75%
Other Operating Expenses	0	-658K	-895K	-968K	-1.02M	-903K
Operating Income+	-10.87M	-12.42M	-14.61M	-3.01M	-24.16M	-31.7M
Operating Margin %	-	-	-	-0.27%	-142.15%	-3962%
Operating Income Growth %	-	-0.14%	-0.18%	0.79%	-7.02%	-0.31%
EBITDA+	-10.49M	-11.76M	-13.72M	-2.04M	-23.15M	-30.79M
EBITDA Margin %	-	-	-	-0.18%	-136.16%	-3849.13%
EBITDA Growth %	-	-0.12%	-0.17%	0.85%	-10.32%	-0.33%
D&A (Non-Cash Add-back)	376K	658K	895K	968K	1.02M	903K
EBIT	-10.87M	-12.42M	-14.56M	-2.7M	-27.48M	-29.87M
Net Interest Income+	-761K	-1.22M	-1.81M	-1.41M	-3.73M	1.46M
Interest Income	0	0	0	0	244K	1.46M
Interest Expense	761K	1.22M	1.81M	1.41M	3.97M	0
Other Income/Expense	-761K	-1.22M	-1.76M	-1.09M	-4.13M	1.83M
Pretax Income+	-11.63M	-13.64M	-16.38M	-4.11M	-28.3M	-29.87M
Pretax Margin %	-	-	-	-0.37%	-166.45%	-3733.63%
Income Tax+	0	0	0	1.1M	0	0
Effective Tax Rate %	1%	1.09%	1.09%	1.27%	1%	1%
Net Income+	-11.63M	-14.86M	-17.8M	-5.21M	-28.3M	-29.87M
Net Margin %	-	-	-	-0.47%	-166.45%	-3733.63%
Net Income Growth %	-	-0.28%	-0.2%	0.71%	-4.43%	-0.06%
Net Income (Continuing)	-11.63M	-13.64M	-16.38M	-5.21M	-28.3M	-29.87M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.49	-0.58	-0.69	-0.21	-1.16	-0.95
EPS Growth %	-	-0.18%	-0.19%	0.7%	-4.52%	0.18%
EPS (Basic)	-0.49	-0.58	-0.69	-0.21	-1.16	-0.95
Diluted Shares Outstanding	23.62M	23.62M	23.62M	24.55M	24.43M	31.45M
Basic Shares Outstanding	23.62M	23.62M	23.62M	24.55M	24.43M	31.45M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	551K	11.48M	5.82M	1.89M	24.2M	31.55M
Cash & Short-Term Investments	425K	11.35M	4.5M	397K	23.19M	30.89M
Cash Only	425K	11.35M	4.5M	397K	9.42M	8.56M
Short-Term Investments	0	0	0	0	13.77M	22.33M
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	126K	0	0	1.5M	1.01M	653K
Total Non-Current Assets+	2.73M	2.53M	2.3M	3.64M	3.69M	3.17M
Property, Plant & Equipment	2.65M	2.45M	2.21M	1.98M	3.6M	3.08M
Fixed Asset Turnover	-	-	-	5.59x	0.05x	0.00x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	80K	80K	92K	1.66M	92K	92K
Total Assets+	3.28M	14.01M	8.13M	5.53M	27.89M	34.72M
Asset Turnover	-	-	-	2.00x	0.01x	0.00x
Asset Growth %	-	3.27%	-0.42%	-0.32%	4.04%	0.24%
Total Current Liabilities+	14.73M	14.49M	22.48M	31.63M	6.55M	6.9M
Accounts Payable	0	927K	4.46M	6.78M	3.78M	5.57M
Days Payables Outstanding	-	514.22	1.82K	2.55K	1.36K	2.25K
Short-Term Debt	4.61M	3.6M	6.16M	16.4M	0	329K
Deferred Revenue (Current)	0	0	1000K	170K	0	0
Other Current Liabilities	10.12M	6.84M	4.11M	5.16M	0	0
Current Ratio	0.04x	0.79x	0.26x	0.06x	3.69x	4.57x
Quick Ratio	0.04x	0.79x	0.26x	0.06x	3.69x	4.57x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	13.37M	22.17M	18.75M	9.69M	1.87M	1.54M
Long-Term Debt	13.04M	21.69M	18.02M	8.52M	0	0
Capital Lease Obligations	322K	476K	731K	1.16M	1.87M	1.54M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0
Total Liabilities	28.09M	36.66M	41.24M	41.31M	8.42M	8.44M
Total Debt+	17.97M	26.06M	25.31M	26.35M	2.52M	1.87M
Net Debt	17.55M	14.71M	20.82M	25.96M	-6.9M	-6.7M
Debt / Equity	-	-	-	-	0.13x	0.07x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-14.28x	-10.17x	-8.05x	-2.14x	-6.08x	-
Total Equity+	-24.81M	-22.66M	-33.11M	-35.78M	19.47M	26.27M
Equity Growth %	-	0.09%	-0.46%	-0.08%	1.54%	0.35%
Book Value per Share	-1.05	-0.96	-1.40	-1.46	0.80	0.84
Total Shareholders' Equity	-24.81M	-22.66M	-33.11M	-35.78M	19.47M	26.27M
Common Stock	24K	27K	9K	9K	27K	35K
Retained Earnings	-154.59M	-168.23M	-184.58M	-189.78M	-221.52M	-251.39M
Treasury Stock	-1.3M	-1.3M	-433K	-433K	-433K	-433K
Accumulated OCI	2K	2K	2K	2K	14K	64K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.22M	-7.21M	-6.58M	-3.57M	-20.27M	-21.23M
Operating CF Margin %	-	-	-	-0.32%	-119.26%	-2653.5%
Operating CF Growth %	-	0%	0.09%	0.46%	-4.68%	-0.05%
Net Income	-11.63M	-13.64M	-16.38M	-5.21M	-28.3M	-29.87M
Depreciation & Amortization	477K	658K	895K	968K	1.02M	903K
Stock-Based Compensation	0	5.33M	4.27M	2.42M	5.2M	6.07M
Deferred Taxes	0	0	348K	0	0	0
Other Non-Cash Items	3.85M	74K	196K	-56K	5.08M	917K
Working Capital Changes	84K	381K	4.08M	-1.69M	-3.28M	751K
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	0	-126K	754K	2.31M	-2.36M	2.16M
Cash from Investing+	-1.77M	-20K	0	-49K	-14.72M	-8.13M
Capital Expenditures	-1.77M	-20K	0	-49K	-1.02M	-381K
CapEx % of Revenue	-	-	-	0%	6.03%	47.63%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	7.89M	18.15M	-270K	-478K	44.02M	28.51M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	145K	-1.45M	4.16M	688K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-8.99M	-7.22M	-6.58M	-3.62M	-21.3M	-21.61M
FCF Margin %	-	-	-	-0.33%	-125.29%	-2701.13%
FCF Growth %	-	0.2%	0.09%	0.45%	-4.88%	-0.01%
FCF per Share	-0.38	-0.31	-0.28	-0.15	-0.87	-0.69
FCF Conversion (FCF/Net Income)	0.62x	0.48x	0.37x	0.69x	0.72x	0.71x
Interest Paid	0	0	0	264K	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-145.31%	-130.58%
Return on Invested Capital (ROIC)	-	-	-	-	-1319.53%	-147.88%
Gross Margin	-	-	-	91.25%	-498.82%	-11187.5%
Net Margin	-	-	-	-47.05%	-16645.29%	-373362.5%
Debt / Equity	-	-	-	-	0.13x	0.07x
Interest Coverage	-14.28x	-10.17x	-8.05x	-2.14x	-6.08x	-
FCF Conversion	0.62x	0.48x	0.37x	0.69x	0.72x	0.71x
Revenue Growth	-	-	-	-	-98.46%	-95.29%

Frequently Asked Questions

Growth & Financials

Genelux Corporation (GNLX) reported $0.0M in revenue for fiscal year 2024.

Genelux Corporation (GNLX) saw revenue decline by 95.3% over the past year.

Genelux Corporation (GNLX) reported a net loss of $31.9M for fiscal year 2024.

Dividend & Returns

Genelux Corporation (GNLX) has a return on equity (ROE) of -130.6%. Negative ROE indicates the company is unprofitable.

Genelux Corporation (GNLX) had negative free cash flow of $24.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener